Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 30

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Dementia Alzheimer's type

Not yet recruiting

Study on the Effects of AD04 and Placebo in Patients with Early Alzheimer's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Aluminium Hydroxide
  • Sponsor:Advantage Therapeutics GmbH

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Embolism

Not yet recruiting

Safety, Tolerability and Pharmacokinetics of Milvexian in Pediatric Patients at Risk of Thromboembolic Events (28 Days to <18 Years)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Milvexian
  • Sponsor:Janssen - Cilag International

Cardiac arrest

Not yet recruiting

Dexmedetomidine for Neuroprotection in Adults After Out‑of‑Hospital Cardiac Arrest – Randomized Placebo‑Controlled Phase II Trial

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Medical University Of Vienna

Triple negative breast cancer+3

Not yet recruiting

Evaluation of DOTATATE and GOZETOTIDE for Diagnosis and Treatment in Patients with Solid Tumors and Brain Metastases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Medica Scientia Innovation Research S.L.

Efficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.